Advertisement


Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease

2016 NCCN Annual Conference (1)

Advertisement

Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.



Related Videos

Lung Cancer

Douglas E. Wood, MD, on Lung Cancer: Workup and Staging

Douglas E. Wood, MD, of the University of Washington, discusses best practices, which enable a complete workup in 1 to 2 weeks in almost all patients, saving unnecessary testing. 

Symptom Management
Survivorship

Joseph B. Narus, DNP, GNP-BC, ANP, on Sexual Function in Survivors: Guideline Update

Joseph B. Narus, DNP, GNP-BC, ANP, of Memorial Sloan Kettering Cancer Center, discusses the impact of cancer treatment on men’s sexual health, and treatment options to improve erectile function.

Breast Cancer

William Gradishar, MD, on Breast Cancer Guideline Updates

William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.

Hepatobiliary Cancer

Anne Covey, MD, on Hepatocellular Carcinoma: Guideline Updates for Locoregional Treatment

Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.

Lung Cancer

Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection

Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.

Advertisement

Advertisement




Advertisement